Compounded vs Brand Tirzepatide
Brand tirzepatide is FDA approved. Compounded tirzepatide is not. Here is what that means for price, safety and the questions to ask before you start.
The short answer
Zepbound and Mounjaro are brand-name tirzepatide drugs approved by the FDA. A compounded version is made by a pharmacy and is not approved. The FDA says compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed.
The FDA says compounded drugs should only be used for patients whose medical needs cannot be met by an approved drug. That is a decision for you and a licensed prescriber, and it is one reason the price alone should not settle it.
Side by side
| Brand tirzepatide | Compounded tirzepatide | |
|---|---|---|
| FDA status | FDA approved (Zepbound for weight management, Mounjaro for type 2 diabetes) | Not FDA approved |
| Safety and quality review | Reviewed by the FDA before marketing | Not reviewed by the FDA before marketing |
| Made by | Eli Lilly | A compounding pharmacy; ask which one |
| Cash price | LillyDirect Zepbound vials: from $299/mo (2.5 mg), $399 (5 mg), $449 for higher doses with refill terms | Varies by provider; we do not publish a range |
| Where it comes from | LillyDirect or a retail pharmacy with a prescription | A pharmacy working with the prescriber or clinic |
LillyDirect prices reviewed November 3, 2026. Lilly can change the program at any time, and the 7.5 mg and higher prices need refills within 45 days. Confirm on the Lilly page.
What the FDA has said
- Tirzepatide shortage resolved: first listed October 2, 2024, confirmed December 19, 2024.
- The periods during which compounders could keep making copies during the shortage have ended for both 503A pharmacies and 503B outsourcing facilities.
- Compounders should not regularly or in inordinate amounts make products that are essentially copies of an approved drug.
- The FDA sent warning letters to 30 telehealth companies on March 3, 2026 over misleading claims about compounded GLP-1s, including implying they are equivalent to approved drugs and not saying who made them.
- Products sold as "for research purposes" or "not for human consumption" are not a legitimate way to get tirzepatide.
- The FDA advises against using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration.
Questions to ask before you pay
- Which pharmacy compounds this, and is it licensed in my state?
- What is in the vial, and at what concentration?
- Why does an FDA-approved drug not meet my needs?
- Who is the prescriber, and are they licensed where I live?
- What is the full monthly cost, including needles, syringes and any membership fee?
- What happens if my dose changes or my shipment arrives warm?
For provider checks, see how to get tirzepatide online safely.
Frequently asked questions
Is compounded tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved drug made by Eli Lilly. Compounded tirzepatide is prepared by a pharmacy, and the FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed. A clinic that implies the two are equivalent is making a claim the FDA has objected to.
Is compounded tirzepatide legal?
The FDA declared the tirzepatide shortage resolved and confirmed that on December 19, 2024. Once a drug is off the shortage list, compounders cannot regularly make products that are essentially copies of the approved drug. The FDA says compounded drugs should only be used for patients whose medical needs cannot be met by an FDA-approved drug. A prescriber has to make that call for you. We are not a source of legal advice.
Why is compounded tirzepatide cheaper?
We do not publish a compounded price range, because prices vary widely and often change. Brand tirzepatide through LillyDirect starts at $299 a month for the 2.5 mg dose and $399 for 5 mg, with $449 for higher doses when refill terms are met. If a compounded price looks far lower, ask what is in the vial, who makes it, and what the total monthly cost is once everything is added up.
Can the FDA still change the rules on compounded tirzepatide?
Yes. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities (503B) may use, saying it found no clinical need for compounding them from bulk substances. The comment period closed on June 29, 2026. We have not found a final decision as of November 3, 2026, so check the FDA page for the current status.
What should I ask a clinic that offers compounded tirzepatide?
Ask which pharmacy compounds it and whether it is licensed in your state, what exactly is in the vial, why an FDA-approved drug does not meet your needs, who prescribes it and where that prescriber is licensed, and what the full monthly cost is including supplies and any membership fee. Get the answers in writing.
Primary sources
- FDA concerns with unapproved GLP-1 drugs used for weight loss
- FDA clarifies policies for compounders as the national GLP-1 supply begins to stabilize
- FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Understanding the risks of compounded drugs
- Zepbound self-pay pricing, LillyDirect (reviewed November 3, 2026)